title: Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs.
authors.affiliation: From the LSE Health, Department of Social Policy, London School of Economics and Political Science, London, United Kingdom (H.N.); Drug Policy Research Group, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA (H.N.); Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands (G.v.V.); School of Social and Community Medicine (J.P.T.H.) and School of Social and Community Medicine (A.E.A.), University of Bristol, Bristol, United Kingdom; Centre for Reviews and Dissemination, University of York, York, United Kingdom (J.P.T.H.); and Program on Comparative Effectiveness Research Methods and Infrastructure, Patient-Centered Outcomes Research Institute, Washington, DC (R.F.). h.naci@lse.ac.uk.
authors.forename: Huseyin
authors.initials: H
authors.lastname: Naci
authors.affiliation: From the LSE Health, Department of Social Policy, London School of Economics and Political Science, London, United Kingdom (H.N.); Drug Policy Research Group, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA (H.N.); Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands (G.v.V.); School of Social and Community Medicine (J.P.T.H.) and School of Social and Community Medicine (A.E.A.), University of Bristol, Bristol, United Kingdom; Centre for Reviews and Dissemination, University of York, York, United Kingdom (J.P.T.H.); and Program on Comparative Effectiveness Research Methods and Infrastructure, Patient-Centered Outcomes Research Institute, Washington, DC (R.F.).
authors.forename: Gert
authors.initials: G
authors.lastname: van Valkenhoef
authors.affiliation: From the LSE Health, Department of Social Policy, London School of Economics and Political Science, London, United Kingdom (H.N.); Drug Policy Research Group, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA (H.N.); Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands (G.v.V.); School of Social and Community Medicine (J.P.T.H.) and School of Social and Community Medicine (A.E.A.), University of Bristol, Bristol, United Kingdom; Centre for Reviews and Dissemination, University of York, York, United Kingdom (J.P.T.H.); and Program on Comparative Effectiveness Research Methods and Infrastructure, Patient-Centered Outcomes Research Institute, Washington, DC (R.F.).
authors.forename: Julian P T
authors.initials: JP
authors.lastname: Higgins
authors.affiliation: From the LSE Health, Department of Social Policy, London School of Economics and Political Science, London, United Kingdom (H.N.); Drug Policy Research Group, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA (H.N.); Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands (G.v.V.); School of Social and Community Medicine (J.P.T.H.) and School of Social and Community Medicine (A.E.A.), University of Bristol, Bristol, United Kingdom; Centre for Reviews and Dissemination, University of York, York, United Kingdom (J.P.T.H.); and Program on Comparative Effectiveness Research Methods and Infrastructure, Patient-Centered Outcomes Research Institute, Washington, DC (R.F.).
authors.forename: Rachael
authors.initials: R
authors.lastname: Fleurence
authors.affiliation: From the LSE Health, Department of Social Policy, London School of Economics and Political Science, London, United Kingdom (H.N.); Drug Policy Research Group, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA (H.N.); Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands (G.v.V.); School of Social and Community Medicine (J.P.T.H.) and School of Social and Community Medicine (A.E.A.), University of Bristol, Bristol, United Kingdom; Centre for Reviews and Dissemination, University of York, York, United Kingdom (J.P.T.H.); and Program on Comparative Effectiveness Research Methods and Infrastructure, Patient-Centered Outcomes Research Institute, Washington, DC (R.F.).
authors.forename: A E
authors.initials: AE
authors.lastname: Ades
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology; D002986:Clinical Trials as Topic; D003657:Decision Making; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D057285:Precision Medicine; D018570:Risk Assessment
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: cardiovascular agents; cardiovascular diseases; coronary disease; decision making, shared; evidence-based medicine; hydroxymethylglutaryl-CoA reductase inhibitors